Dual antiplatelet therapy with aspirin and clopidogrel is a standard care to reduce the risk of recurrent cardiovascular events in patients with acute coronary syndrome (ACS). The dual treatment has demonstrated substantial benefit in patients undergoing percutaneous coronary intervention (PCI) and stent implantation. Despite adequate treatment, major adverse cardiovascular events (MACE) occur in about 10% of patients on dual antiplatelet therapy. Genetic variants in CYP2C19 gene have been associated with residual platelet reactivity on-clopidogrel treatment and adverse outcomes in high risk vascular patients. The introduction of pharmacogenetic tests, in addition to platelet function test, could provide the clinician with an additional tool to make decisions on differentiated therapeutic strategies, tailored antiplatelet therapy, modeled on the individual characteristics of the patients, amplifying the concept of "personalized medicine". The use of genetic test for the identification of CYP2C19*2 and other polymorphisms involved in the pharmacogenetics of clopidogrel could thus be useful to improve the risk stratification of patients, guide clinicians in the choice for alternative antiplatelet therapy, and therapeutic management of patients, and consequently to reduce the occurrence of MACE in patients with ACS. Rapid point of care genetic tests would be desirable to allow cardiologists and primary care physicians to obtain a rapid genetic profile of patients under treatment and integrate this information in an accurate predictive algorithm to achieve truly antiplatelet personalized care. This expert review provides an analysis of the currently available biotechnologies for clopidogrel pharmacogenetics testing and what we can anticipate in the near future for personalized medicine. © 2013 Bentham Science Publishers.

Pharmacogenetic testing for clopidogrel: State of the ART / Saracini, Claudia; Galora, Silvia; Palombella, Anna Maria; Abbate, Rosanna; Giusti, Betti. - In: CURRENT PHARMACOGENOMICS AND PERSONALIZED MEDICINE. - ISSN 1875-6921. - ELETTRONICO. - 11:(2013), pp. 203-215. [10.2174/18756921113119990002]

Pharmacogenetic testing for clopidogrel: State of the ART

SARACINI, CLAUDIA;GALORA, SILVIA;PALOMBELLA, ANNA MARIA;ABBATE, ROSANNA;GIUSTI, BETTI
2013

Abstract

Dual antiplatelet therapy with aspirin and clopidogrel is a standard care to reduce the risk of recurrent cardiovascular events in patients with acute coronary syndrome (ACS). The dual treatment has demonstrated substantial benefit in patients undergoing percutaneous coronary intervention (PCI) and stent implantation. Despite adequate treatment, major adverse cardiovascular events (MACE) occur in about 10% of patients on dual antiplatelet therapy. Genetic variants in CYP2C19 gene have been associated with residual platelet reactivity on-clopidogrel treatment and adverse outcomes in high risk vascular patients. The introduction of pharmacogenetic tests, in addition to platelet function test, could provide the clinician with an additional tool to make decisions on differentiated therapeutic strategies, tailored antiplatelet therapy, modeled on the individual characteristics of the patients, amplifying the concept of "personalized medicine". The use of genetic test for the identification of CYP2C19*2 and other polymorphisms involved in the pharmacogenetics of clopidogrel could thus be useful to improve the risk stratification of patients, guide clinicians in the choice for alternative antiplatelet therapy, and therapeutic management of patients, and consequently to reduce the occurrence of MACE in patients with ACS. Rapid point of care genetic tests would be desirable to allow cardiologists and primary care physicians to obtain a rapid genetic profile of patients under treatment and integrate this information in an accurate predictive algorithm to achieve truly antiplatelet personalized care. This expert review provides an analysis of the currently available biotechnologies for clopidogrel pharmacogenetics testing and what we can anticipate in the near future for personalized medicine. © 2013 Bentham Science Publishers.
2013
11
203
215
Saracini, Claudia; Galora, Silvia; Palombella, Anna Maria; Abbate, Rosanna; Giusti, Betti
File in questo prodotto:
File Dimensione Formato  
Pharmacogenetic Testing for Clopidogrel_ State of the ART CPPM 2013.pdf

Accesso chiuso

Descrizione: Articolo principale
Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 541.05 kB
Formato Adobe PDF
541.05 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1086377
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact